Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

American Airlines Group ( NASDAQ: AAL) may be looking to get more competitive with its peers. The airline is planning to test ...

The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...

CVS struggled financially last year after underpricing some Aetna insurance plans and the government lowered quality ratings.

The Net Promoter System, and the bonuses associated with it, has taken companies off focus.

Reports Q4 revenue $120.8M, consensus $129.42M. Lee Bienstock, Chief Executive Officer of DocGo (DCGO), commented, “We continue to experience ...